| abstract |
The invention relates to medicine and can be used to determine the risk of fibrotic changes in the lungs and liver. The present invention is to simplify and increase the reliability of determining the risk of developing and predicting fibrotic changes in the lungs and liver during medical examinations of a large number of workers in hazardous working conditions for a short time. This task is achieved by the fact that the proposed method for determining the risk of fibrotic changes in the lungs and human liver involves sampling venous blood, isolating total DNA, preparing an amplification mixture using specific primers with TaqMan probes, conducting real-time polymerase chain reaction, and determining the presence of or the absence of Z-and S-mutations of the a1-proteinase inhibitor gene, while the risk of fibrotic changes in the lungs and liver in the absence of the Z and S mutations is less than 20%, in the presence of a heterozygous S-mutation 20-40%, a heterozygous Z mutation 50-80%, a homozygous S mutation 40-60%, a homozygous Z mutation more than 80%. |